Supernus Pharmaceuticals Inc
SWB:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
SWB:S49
|
US |
|
F
|
Fastenal Co
XHAM:FAS
|
US |
|
Hisamitsu Pharmaceutical Co Inc
OTC:HTSUY
|
JP |
|
S
|
Steel Dynamics Inc
XMUN:SD5
|
US |
|
Community Healthcare Trust Inc
F:4U9
|
US |
|
C
|
Credit Suisse Group AG
F:CSX
|
CH |
|
Green Plains Inc
NASDAQ:GPRE
|
US |
|
Barclays PLC
LSE:BARC
|
UK |
|
Hyundai Motor Co
F:HYU
|
KR |
|
T
|
Thonburi Healthcare Group PCL
SET:THG
|
TH |
|
Iberdrola SA
MAD:IBE
|
ES |
|
S
|
Societe Generale SA
DUS:SGE
|
FR |
|
S
|
Schneider Electric SE
XBER:SND
|
FR |
|
P
|
Progressive Corp
DUS:PGV
|
US |
|
Agree Realty Corp
F:AGL
|
US |
|
L
|
Link Real Estate Investment Trust
F:L5R
|
HK |
|
Vext Science Inc
F:VV5
|
CA |
|
S
|
Safehold Inc
F:2T3
|
US |
|
Intesa Sanpaolo SpA
MIL:ISP
|
IT |
|
Main Street Capital Corp
NYSE:MAIN
|
US |
|
D
|
DXC Technology Co
BMV:DXC
|
US |
|
A
|
AP Thailand PCL
SET:AP
|
TH |
|
V
|
Valneva SE
XMUN:AYJ
|
FR |
|
F
|
Fresnillo PLC
F:FNL
|
MX |
Wall St Price Targets
S49 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for S49 is 55.45 EUR with a low forecast of 48.24 EUR and a high forecast of 61.09 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S49's stock price target?
Price Target
55.45
EUR
According to Wall Street analysts, the average 1-year price target for S49 is 55.45 EUR with a low forecast of 48.24 EUR and a high forecast of 61.09 EUR.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
